Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with peripheral T-cell lymphoma: a meta-analysis

Previous studies have explored whether soluble programmed cell death ligand-1 (sPD-L1) can be used to predict the prognosis of patients with peripheral T-cell lymphoma (PTCL); however, no consistent results have been obtained. Consequently, we conducted the present meta-analysis to identify the precise significance of sPD-L1 in predicting the prognosis of PTCL. We searched PubMed, Embase, Web of Science, and the Cochrane Library until July 31, 2024. The value of sPD-L1 in predicting PTCL prognosis was examined by combining the hazard ratios (HRs) with 95% confidence intervals (CIs). Seven articles involving 445 patients were included in this study. Based on our pooled findings, increased sPD-L1 was associated with dismal overall survival (OS) (HR = 4.22, 95%CI = 1.89–9.43, p p = 0.004) in PTCL. Furthermore, higher sPD-L1 levels were correlated with male sex (OR = 1.80, 95%CI = 1.06–3.03, p = 0.029), International Prognostic Index (IPI) score ≥2 (OR = 4.32, 95%CI = 2.10–8.89, p p = 0.001), presence of B symptoms (OR = 2.56, 95%CI = 1.45–4.52, p = 0.001), and ECOG PS ≥2 (OR = 7.41, 95%CI = 1.49–36.92, p = 0.015) in PTCL. According to the present meta-analysis, higher sPD-L1 levels were significantly correlated with poor OS and inferior PFS in patients with PTCL. Additionally, high sPD-L1 levels were also associated with clinical features representing the development of PTCL. The present meta-analysis has first explored the impact of sPD-L1 on forecasting PTCL prognosis.Higher sPD-L1 level was significantly correlated with dismal OS and inferior PFS of PTCL patients.High sPD-L1 was also connected to clinical features representing the disease development of PTCL. The present meta-analysis has first explored the impact of sPD-L1 on forecasting PTCL prognosis. Higher sPD-L1 level was significantly correlated with dismal OS and inferior PFS of PTCL patients. High sPD-L1 was also connected to clinical features representing the disease development of PTCL.

既往研究已探讨可溶性程序性细胞死亡配体1（soluble programmed cell death ligand-1, sPD-L1）是否可用于预测外周T细胞淋巴瘤（peripheral T-cell lymphoma, PTCL）患者的预后，但尚未获得一致结论。因此，本研究开展此项荟萃分析，以明确sPD-L1在预测PTCL预后中的确切价值。我们检索了PubMed、Embase、Web of Science及Cochrane Library数据库，检索时限截至2024年7月31日。通过合并风险比（hazard ratio, HR）与95%置信区间（confidence interval, CI），评估sPD-L1对PTCL预后的预测价值。本研究共纳入7项研究，涉及445例患者。基于合并分析结果，PTCL患者中sPD-L1水平升高与较差的总生存期（overall survival, OS）显著相关（HR=4.22，95%CI=1.89~9.43，P=0.004）。此外，sPD-L1水平升高还与男性性别（比值比odds ratio, OR=1.80，95%CI=1.06~3.03，P=0.029）、国际预后指数（International Prognostic Index, IPI）评分≥2分（OR=4.32，95%CI=2.10~8.89，P=0.001）、存在B症状（OR=2.56，95%CI=1.45~4.52，P=0.001）及东部肿瘤协作组体能状态评分（ECOG PS）≥2分（OR=7.41，95%CI=1.49~36.92，P=0.015）显著相关。本项荟萃分析结果显示，sPD-L1水平升高与PTCL患者较差的总生存期及更短的无进展生存期（progression-free survival, PFS）显著相关。此外，sPD-L1高表达还与反映PTCL疾病进展的多项临床特征相关。本研究首次探讨了sPD-L1对PTCL预后的预测价值。